Castle Biosciences, Inc.
CSTL
$18.63
-$0.41-2.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 339.92M | 344.23M | 343.53M | 346.27M | 347.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 339.92M | 344.23M | 343.53M | 346.27M | 347.08M |
| Cost of Revenue | 75.18M | 71.03M | 68.90M | 65.80M | 62.69M |
| Gross Profit | 264.74M | 273.20M | 274.63M | 280.47M | 284.39M |
| SG&A Expenses | 235.60M | 229.32M | 222.56M | 217.15M | 210.17M |
| Depreciation & Amortization | 8.74M | 14.74M | 16.80M | 16.80M | 17.08M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 373.21M | 366.94M | 358.36M | 349.22M | 340.77M |
| Operating Income | -33.29M | -22.71M | -14.83M | -2.95M | 6.31M |
| Income Before Tax | -17.66M | -29.51M | -18.92M | -10.25M | -2.22M |
| Income Tax Expenses | -4.82M | -5.36M | -6.68M | -781.00K | 2.85M |
| Earnings from Continuing Operations | -12.83 | -24.16 | -12.24 | -9.47 | -5.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.83M | -24.16M | -12.24M | -9.47M | -5.07M |
| EBIT | -33.29M | -22.71M | -14.83M | -2.95M | 6.31M |
| EBITDA | -16.54M | -223.70K | 9.64M | 19.44M | 28.63M |
| EPS Basic | -0.43 | -0.84 | -0.42 | -0.32 | -0.16 |
| Normalized Basic EPS | -0.48 | -0.24 | -0.05 | 0.22 | 0.42 |
| EPS Diluted | -0.44 | -0.85 | -0.46 | -0.36 | -0.20 |
| Normalized Diluted EPS | -0.48 | -0.24 | -0.07 | 0.20 | 0.40 |
| Average Basic Shares Outstanding | 117.21M | 115.93M | 114.72M | 113.49M | 112.22M |
| Average Diluted Shares Outstanding | 117.84M | 116.56M | 117.43M | 117.76M | 116.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |